Covalon Technologies Ltd. [TSX-V: COV] | Top Medical Device Manufacturing Company in APAC 2019

MedTech Outlook Magazine

Covalon Technologies Ltd. [TSX-V: COV]
COV] - Advancing Infection Prevention with Innovative Solutions

Alyssa Hrycyshyn, VP of Marketing, Covalon Technologies Ltd. [TSX-V: COV]Alyssa Hrycyshyn, VP of Marketing
Increased incidence of antibiotic resistance has heightened the awareness of the growing need to advance healthy healing through novel and innovative solutions in infection prevention. Having spotted this need, a group of entrepreneurial PhDs from the University of Toronto, Ontario, Canada, endeavoured to address these issues, and as a result, Covalon Technologies Ltd. [TSXV: COV] was established.

The Ontario-based medical devices manufacturer researches, develops, and commercializes healthcare innovations to manage and prevent infections related (but not limited) to advanced and chronic wounds, vascular access, and the perioperative space. Covalon Technologies’ product breadth currently spans a range of innovative healing and preventive devices including self-adherent silicones with antimicrobial agents, alginates, hydrocolloids, and new and novel advanced collagen biomatrix dressings. Alongside these commercialized products, Covalon Technologies, through its OEM segment, partners with many small, medium, and large medical device organizations to either co-create novel technologies, or support the development and commercialization of new products in various geographic markets and therapeutic areas. By working with these organizations, Covalon enables the advancement of products by incorporating active pharmaceutical ingredients (APIs) into its proprietary surface modification and coating capabilities. Alyssa Hrycyshyn, VP of Marketing at Covalon, says, “Through both our product and service segments, we aim to be the primary solutions provider to support infection prevention management in wound healing and medical device technology development.”

The organization’s novel perioperative line provides protection throughout the patient’s entire surgical journey. Beginning with MediClear® PreOp, a transparent, dual antimicrobial self-adherent silicone dressing applied after admission and worn into the OR to post surgical site protection with SurgiClearTM, an antimicrobial transparent protection and wound site monitoring, and post surgical scar management with MediClear™ Scar for managing the prevention of keloid and hyertrophic scars.

The breadth and depth of their advanced wound care portfolio showcases the organizations commitment to commercializing solutions for innovative healing.

Covalon’s product breadth and OEM service offerings currently span a range of healing, barrier protection and antimicrobial collagens, alginates, hydrocolloids, advanced biomatrix, and transparent silicone dressings, in addition to surface modification and coating capabilities

It’s ColActive® Plus, and ColActive® Plus Ag combine multiple mechanisms of action, (typically achieved with 4-5 different products), to accelerate wound repair in a single dressing alone, a prime example of how Covalon’s scientists develop formulations to improve capacity for healing.

In the case of their OEM segment, “Our experienced team, which comprises cross-disciplinary scientists and PhDs, work closely with each client to develop customized medical devices that provide superior performance (and durability) through our world-class surface modification and coating capabilities,” informs Alyssa. These competencies have enabled Covalon Technologies to position itself to address gaps or deficiencies in workflow or existing technologies which pose opportunity for infection. An example of this is the firm’s application of its proprietary, low particulate medical coating for interventional medical devices. Covalon Technologies first commercial device, the SilverCoat® Silicone Foley catheter, incorporated CovaCoat® Technology which provided clinicians an FDA-approved, device with an innovative and proprietary, antimicrobial coating to help reduce catheter related urinary tract infections.

“Whether it is a patient with compromised skin integrity, an aged diabetic patient with a complex chronic wound, or a med device company seeking assistance on surface modification or the incorporation of APIs, we have the know-how to develop technologies to promote infection prevention and advance patient health and quality of care,” states Alyssa.

The key to Covalon’s steady success lies in its ability to thoroughly understand the needs of the patient and its customers, to deliver products of the highest quality. This proficiency has garnered the firm a global presence across the Americas, APAC, and EMEA regions. Going forward, the company will continue to develop additional technologies and formulations that reduce infection and improve patient outcomes. With healthcare professionals increasingly seeking ways to accelerate healing and improve the quality of care, Covalon Technologies sits at a unique intersection, bringing a transformational change in the way infection prevention is managed.

Top 10 Medical Device Manufacturing Companies in APAC- 2019

Company
Covalon Technologies Ltd. [TSX-V: COV]

Management
Alyssa Hrycyshyn, VP of Marketing

Description
A medical device manufacturer that combines science and technology to innovate healthcare medical devices by developing and commercializing medical technologies using proprietary design and development methodologies to advance treatment of advanced and chronic wounds, and promote infection prevention strategies across the healthcare continuum. Covalon Technologies was founded in 2004 by a group of with entrepreneurial PhDs from the University of Toronto, who recognized the opportunity to apply scientific method to innovate patented and advance healing alternatives in the global wound market. At its core, the Covalon team is comprised of cross-functional members who work closely to develop medical technologies using its proprietary antimicrobial formulations and/or its pioneering design and development approach to surface modification and coating to support infection prevention, and healthy healing strategies to improve the quality (and value) of care

Covalon Technologies Ltd. [TSX-V: COV] News

Infection Prevention Solutions Provider Covalon to Participate for the First Time in NEO - The Conference for Neonatology in Las Vegas, NV on February 22-24, 2023

Visit booth 100 to learn how Covalon's products are uniquely designed to help prevent CLABSIs and SSIs while providing more gentle, compassionate experiences for neonates and young children.
MISSISSAUGA, ON - Covalon Technologies Ltd. announced its participation for the first time in the Conference for Neonatology in Las Vegas, Nevada from Wednesday, February 22 to Friday, February 24, 2023 ("NEO"). The NEO conference brings together global experts, healthcare providers, academia, and industry, with a focus on improving the level of care being provided to infants in neonatal intensive care units ("NICUs"). Healthcare providers looking for solutions that help prevent infection, improve patient outcomes, and reduce stress on care providers should visit Covalon at booth 100 to learn more about the unique compassionate care solutions Covalon provides to top pediatric hospitals throughout the United States.
Compassionate Care Requires Compassionate Technology (CNW Group/Covalon Technologies Ltd.)
NEO was designed for participants to better understand and utilize the leading approaches to neonatal intensive care. Amongst renowned experts in neonatal-perinatal care, Covalon will be presenting its compassion-driven, innovative solutions designed specifically to help protect infants and children from infection, while reducing stress and suffering in both patients and care providers
"Every child deserves an equal opportunity to reach their full potential," said Ron Hebert, Senior Vice President, Global Marketing, Covalon. "We now know how important the first weeks of life are, and it's critical that we work to help support lifelong favorable outcomes with unique, patient-centered and compassion-driven medical technology. Major pediatric hospitals have implemented use of Covalon's infection prevention solutions and have gone on to observe improving infection rates." Covalon's compassionate care technology is already being utilized by 6 of the top 10 children's hospitals, as ranked by U.S. News & World Report, and is quickly becoming a standard of care in many prestigious pediatric hospitals across the U.S.
Covalon's infection prevention solutions include:
• VALGuard® - an FDA listed, transparent, environmental barrier designed to protect catheter hubs and line connections from external contaminants and gross contamination, including body fluids and other secretions. It incorporates a quick-release pull strip for fast access to infusion hubs and for easy removal.
• IV Clear® - the world's only dual-antimicrobial vascular access dressing that offers complete transparency at and around the insertion site for easy daily assessment. It uses a soft silicone adhesive to minimize skin injuries and preserve skin barrier functions and incorporates safe amounts of antimicrobials, without sacrificing efficacy, to protect against chemical irritation.
• SurgiClear® - the world's only dual-antimicrobial clear postoperative dressing that provides full surgical site visibility, allowing for visual site inspection and thus eliminating the need for early and multiple dressing removals.
• CovaClear® IV – utilizes the same trusted silicone adhesive technology to protect patients from skin injuries but does not incorporate antimicrobials for use with patients who either don't require or cannot tolerate antimicrobials.